Cometriq Fails to Meet Primary Endpoint in Metastatic Castration-Resistant Prostate Cancer
News
Exelixis, Inc. has announced the results from its COMET-1 phase 3 trial on cabozantinib for the treatment of metastatic castration-resistant prostate cancer (mCRPC) did not meet the primary endpoint of overall ... Read more